Research article summary (published 13 Nov 1999):

[The combination of insulin and metformin in obese patients with type-2 diabetes mellitus]

(Asociación de insulina y metformina en pacientes obesos con diabetes mellitus tipo 2.)

Full Abstract

OBJECTIVES: Principal: to show that the addition of metformin to insulin treatment in type-2 DM obese patients with poor metabolic control (HbA1c > 7.5%) causes a 50% increase after one year in the number of patients with acceptable (HbA1c < or = 7.5%) or good (HbA1c < 6.5%) control, and to determine how many patients reduced their HbA1c by a point. Secondary: to determine the relationship between the BMI at the start of treatment and the difference between HbA1c values before and after treatment. DESIGN: Quasi-experimental before-and-after intervention study. SETTING: Diabetes clinic at the San Carlos Hospital, consisting of patients referred from primary care. PATIENTS: 31 obese people with type-2 DM and with poor metabolic control (HbA1c > 7.5%) in spite of insulin treatment were chosen by consecutive sampling as they attended for consultation. Three people left due to their intolerance of metformin. INTERVENTIONS: Metformin was added progressively over a year in total doses of 1.7 mg. All those parameters considered in diabetes control were measured, the main criterion of evaluation being the HbA1c figures. MEASUREMENTS AND RESULTS: Patients with poor metabolic control changed from 100% at the start of the study to 42.9% after a year (p = 0.0000). There was a 1.75% mean reduction of HbA1c. 78.57% of patients reduced their HbA1c by a point. The relationship between the BMI before the start of treatment and the HbA1c difference at the start and end gave a Pearson's correlation coefficient of r = -0.39 (p = 0.04). CONCLUSIONS: Adding metformin to the treatment of obese type-2 DM patients with poor metabolic control and on insulin treatment improved their control.

Author information

Author/s: Sánchez-Barba Izquierdo, M I (MI); Ibarra Rueda, J M (JM); Ruiz de Adana Pérez, R (R);

Affiliation: Centro de Salud Espronceda, Madrid. pir(-atsign-)mx3.redetebs.es

Journal and publication information

Publication Type: Clinical Trial; Comparative Study; English Abstract; Journal Article

Journal: Atencion primaria / Sociedad Española de Medicina de Familia y Comunitaria (Aten Primaria), published in SPAIN. (Language: spa)

Reference: 1999-Nov; vol 24 (issue 8) : pp 462-7

Dates: Created 2000/01/28; Completed 2000/01/28; Revised 2006/11/15;

PMID: 10630028, status: MEDLINE (last retrieved date: 2/18/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Albuminuria - urine Blood Glucose - analysis; drug effects Diabetes Mellitus - blood; drug therapy; urine Diabetes Mellitus, Type 2 - blood; drug therapy; urine Drug Therapy, Combination Female Hemoglobin A, Glycosylated - analysis; drug effects Humans

Humans Hypoglycemic Agents - administration & dosage Insulin - administration & dosage Male Metformin - administration & dosage Middle Aged Obesity Time Factors

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: Blood Glucose (0) ; Hemoglobin A, Glycosylated (0) ; Hypoglycemic Agents (0) ; Insulin (11061-68-0) ; Metformin (657-24-9)

Related articles

These are the most related articles currently in our database:

• PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. 29 Apr 2007
• Focus on metformin - a major cardiovascular medication. 'Diabesity - the biggest epidemic in human history'. 30 Aug 2007
• Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. 30 Oct 2007
• [Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care] 13 Aug 2006
• Macronutrient intake, glycaemic index and glycaemic load of older Australian subjects with and without diabetes: baseline data from the Blue Mountains Eye study. 29 Jun 2006
• Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus. 12 Jul 2006
• Inhaled dry powder insulin for the treatment of diabetes mellitus. 29 Apr 2007
• Patient-centred and professional-directed implementation strategies for diabetes guidelines: a cluster-randomized trial-based cost-effectiveness analysis. 30 Jan 2006
• Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients. 23 Jan 2006
• Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. 29 Jun 2006

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a larger map of 100+ related articles.